Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next?
Multistakeholder Perceptions of Additional Value Elements for United States Value Assessment of Health Interventions
Appropriate Categorization of Inequality to Inform Policy Decisions: Estimating Distribution of Lifetime Health Using Alternative Approaches to Socioeconomic Stratification
Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival
Two Methods, One Story? Comparing Results of a Choice Experiment and Multidimensional Thresholding From a Clinician Preference Study in Aneurysmal Subarachnoid Hemorrhage
Applying Trial-Derived Treatment Effects to Real-World Populations: Generalizing Cost-Effectiveness Estimates When Modeling Complex Hazards
Patient-Reported Outcome-Based Performance Measures in Alternative Payment Models: Current Use, Implementation Barriers, and Principles to Succeed
Microsimulation Models on Mental Health: A Critical Review of the Literature
Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs
Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data
Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters
Evaluating Policies of Expanding Versus Restricting First-Line Treatment Choices: A Cost-Effectiveness Analysis Framework
Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology
Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis Patients
Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report
Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study
Public Acceptance of Measures to Control Infectious Diseases Under Different Scenarios of Severity and Transmissibility
It Is Time to Reconsider the 3% Discount Rate
Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now
×